Transamerica Financial Advisors Inc. boosted its stake in Thermo Fisher Scientific Inc (NYSE:TMO) by 0.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,943 shares of the medical research company’s stock after buying an additional 4 shares during the period. Transamerica Financial Advisors Inc.’s holdings in Thermo Fisher Scientific were worth $606,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of TMO. Federated Investors Inc. PA boosted its stake in shares of Thermo Fisher Scientific by 14.7% in the fourth quarter. Federated Investors Inc. PA now owns 9,431 shares of the medical research company’s stock worth $1,331,000 after buying an additional 1,210 shares during the period. Janus Capital Management LLC boosted its stake in shares of Thermo Fisher Scientific by 36.6% in the fourth quarter. Janus Capital Management LLC now owns 3,491,101 shares of the medical research company’s stock worth $492,608,000 after buying an additional 935,955 shares during the period. Glenview Capital Management LLC acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $516,388,000. GLG LLC boosted its stake in shares of Thermo Fisher Scientific by 6.8% in the fourth quarter. GLG LLC now owns 13,646 shares of the medical research company’s stock worth $1,925,000 after buying an additional 868 shares during the period. Finally, Caxton Associates LP acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $5,644,000. 87.15% of the stock is currently owned by institutional investors.

Shares of Thermo Fisher Scientific Inc (NYSE:TMO) traded up 0.58% during midday trading on Monday, reaching $177.35. The company’s stock had a trading volume of 792,038 shares. The stock’s 50-day moving average price is $176.88 and its 200-day moving average price is $164.14. Thermo Fisher Scientific Inc has a 12-month low of $139.07 and a 12-month high of $182.87. The company has a market cap of $69.17 billion, a P/E ratio of 30.90 and a beta of 1.06.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.27 by $0.03. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The firm had revenue of $5 billion for the quarter, compared to analysts’ expectations of $4.92 billion. During the same quarter last year, the firm earned $2.03 earnings per share. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. On average, analysts expect that Thermo Fisher Scientific Inc will post $9.24 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 15th will be paid a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.34%. The ex-dividend date is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.45%.

COPYRIGHT VIOLATION WARNING: “Thermo Fisher Scientific Inc (NYSE:TMO) Position Boosted by Transamerica Financial Advisors Inc.” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/08/07/transamerica-financial-advisors-inc-has-606000-position-in-thermo-fisher-scientific-inc-nysetmo-updated-updated-updated.html.

A number of equities analysts recently issued reports on the stock. Bank of America Corporation reiterated a “buy” rating and issued a $210.00 price target (up previously from $200.00) on shares of Thermo Fisher Scientific in a research note on Friday, July 21st. Barclays PLC reissued an “overweight” rating and issued a $200.00 target price (up previously from $190.00) on shares of Thermo Fisher Scientific in a research report on Monday, July 17th. Cleveland Research raised Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research report on Thursday, July 20th. Wells Fargo & Company reaffirmed an “outperform” rating and set a $200.00 price target (up previously from $195.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 13th. Finally, Citigroup Inc. reaffirmed a “buy” rating and set a $201.00 price target (up previously from $182.00) on shares of Thermo Fisher Scientific in a research report on Monday, July 10th. One research analyst has rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $188.56.

In related news, CFO Stephen Williamson sold 2,500 shares of the business’s stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $176.26, for a total value of $440,650.00. Following the completion of the sale, the chief financial officer now directly owns 37,790 shares of the company’s stock, valued at $6,660,865.40. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Marc N. Casper sold 20,000 shares of the business’s stock in a transaction dated Thursday, June 1st. The shares were sold at an average price of $172.79, for a total value of $3,455,800.00. Following the completion of the sale, the chief executive officer now directly owns 269,279 shares of the company’s stock, valued at $46,528,718.41. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 27,188 shares of company stock worth $4,702,223. 0.49% of the stock is currently owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.